Presentation is loading. Please wait.

Presentation is loading. Please wait.

Representative patient responses to ulixertinib.

Published byÖzlem Ulusoy Modified over 4 years ago

Similar presentations

Presentation on theme: "Representative patient responses to ulixertinib."— Presentation transcript:

1 Representative patient responses to ulixertinib.
Representative patient responses to ulixertinib. Longitudinal radiographic scans from a subset of patients who responded to ulixertinib are shown. A, A patient with gallbladder adenocarcinoma with a BRAF L485W mutation who experienced partial response in two lesions (green circles) over 12 weeks. B, A patient with glioblastoma multiforme with a BRAF V600E mutation who experienced a 64% reduction of their tumor (green circles) after 10 cycles of treatment with ulixertinib. Ryan J. Sullivan et al. Cancer Discov 2018;8: ©2018 by American Association for Cancer Research

Download ppt "Representative patient responses to ulixertinib."

Similar presentations

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Figure 1. A: T1-weighted MRI shows enhanced lesion with peripheral edema on left frontal area, compatible with high grade glioma. B: Left frontal area.

Figure 1. A: T1-weighted MRI shows enhanced lesion with peripheral edema on left frontal area, compatible with high grade glioma. B: Left frontal area.
Dose-escalation patient response.

Dose-escalation patient response.
Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Genomic alterations in breast cancer cell line MDA-MB-231.

Genomic alterations in breast cancer cell line MDA-MB-231.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.

Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.

Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.
BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.
Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.
Carrie C. Lubitz, Sareh Parangi, Tammy M. Holm, M

Carrie C. Lubitz, Sareh Parangi, Tammy M. Holm, M
Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. Note.

A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. Note.
Partial pedigrees for novel INS mutations identified in probands with MODY and young type 2 diabetes. Partial pedigrees for novel INS mutations identified.

Partial pedigrees for novel INS mutations identified in probands with MODY and young type 2 diabetes. Partial pedigrees for novel INS mutations identified.
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Similar presentations

Ads by Google